Prudential Financial
XERS icon

Prudential Financial’s Xeris Biopharma Holdings XERS Stock Holding History

Prudential Financial’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Sell
28,089
-29,050
-51% -$186K ﹤0.01% 2198
2026
Q1 		$331K Sell
57,139
-561,810
-91% -$3.73M ﹤0.01% 1994
2025
Q4 		$4.86M Sell
618,949
-815,255
-57% -$6.42M 0.01% 931
2025
Q3 		$11.7M Sell
1,434,204
-122,425
-8% -$813K 0.01% 603
2025
Q2 		$7.27M Buy
1,556,629
+457,784
+42% +$2.1M 0.01% 748
2025
Q1 		$6.03M Buy
1,098,845
+1,061,900
+2,874% +$4.29M 0.01% 765
2024
Q4 		$125K Buy
36,945
+7,000
+23% +$22.5K ﹤0.01% 2129
2024
Q3 		$85.3K Buy
+29,945
New +$76.9K ﹤0.01% 2593
2024
Q2 		– Sell
-28,675
Closed -$63.4K – 2797
2024
Q1 		$63.4K Sell
28,675
-2,800
-9% -$7.24K ﹤0.01% 2575
2023
Q4 		$74K Hold
31,475
– – ﹤0.01% 2520
2023
Q3 		$58.5K Sell
31,475
-127,400
-80% -$292K ﹤0.01% 2485
2023
Q2 		$416K Buy
+158,875
New +$404K ﹤0.01% 2198

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Prudential Financial's XERS Position: Q2 2026 in Review

Prudential Financial reduced its Xeris Biopharma Holdings (XERS) stake by 51% in Q2 2026, selling an estimated $186K and leaving 28,089 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #2198.

Prudential Financial first reported a position in XERS in Q2 2023 and has held it in 12 quarters since. The position peaked at $11.7M in Q3 2025. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Prudential Financial held 28,089 shares of Xeris Biopharma Holdings worth $222K as of Q2 2026.
  • Prudential Financial sold 29,050 Xeris Biopharma Holdings shares in Q2 2026, an estimated $186K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #2198 holding.
  • Prudential Financial first reported a position in Xeris Biopharma Holdings in Q2 2023 and has held it in 12 quarters since.
  • Prudential Financial's Xeris Biopharma Holdings position peaked at $11.7M in Q3 2025.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.